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Kevin P Killeen PhD 
Chief Scientific Officer 
Matrivax Research & Development Corp. 
Boston, Massachusetts, USA 
 
Development of Protein Capsular Matrix Vaccine Technology  
ECI Portugal 2016 
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• Founders/Board of Directors:  
• John J Mekalanos, PhD- Professor, Harvard Medical School 
• Yichen Lu, PhD- Professor, Harvard School Public Health; President & CEO, VTI 
• Gerald Chan, PhD- Director Hang Lung Group Limited and Morningside  
  
• Matrivax is a biotechnology company incorporated in October 2007, funded by 
Morningside Ventures, headquartered in Boston, MA; 18 FTEs  
 
• Protein Capsular Matrix Vaccine (PCMV) technology, ‘virtual conjugation’, exclusively 
licensed from Harvard Medical School. Potential to transform complex ‘conjugate’ vaccine 
manufacture (e.g. pneumococcal and meningococcal vaccines) by enabling simplified, low-
cost production and extensive market penetration 
 
• Strategic Alliance with Vaccine Technologies Inc. (VTI) to construct a 3,000 square meter 
GMP vaccine pilot manufacturing facility in Haikou China to GMP manufacture 




• Merck Pneumovax® - 23-valent vaccine - no long term efficacy 
• GSK Synflorix® -10-valent - limited in vaccine coverage 
• Pfizer Prevnar®  $6 B in sales in 2015; Worldwide market projected to $8 billion ($5 billion in 
low-to-middle income markets) 
Meningococcal Vaccines 
• Sales of sanofi Menactra®  - quadrivalent conjugate; ages 2-55;  >$1B sales 
• Novartis launched quadrivalent conjugate, Menveo® 
Enteric Fever Vaccines 
• Typhim Vi ® and Vivotif ® moderate protective efficacy ~70% 
• Typhoid fever market alone >$200MM; combination paratyphoid A projected >$350MM 
Clostridium difficile Vaccines 
• No commercialized vaccine; sanofi toxoid based candidate in Phase 3   
• C. difficile vaccine market projected > $1B sales 
Targeted Polysaccharide Vaccine Markets 
Conjugation covalently bonds 
PS to Protein  
PCMV entraps PS in protein 
matrix  
Protein PS Crosslinker 
4 
Conjugation versus PCMV  technology 
 
Multivalent conjugate vaccine Multivalent PCMV 
Protein PS Crosslinker 





Conjugation versus PCMV  technology 
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Serotypes 23 valent Prevnar Synflorix Prevnar13  
          
1 X   X X 
2 X       
3 X     X 
4 X X X X 
5 X   X X 
6A       X 
6B X X X X 
7F X   X X 
8 X       
9N X       
9V X X X X 
10A X       
11A X       
12F X       
14 X X X X 
15B X       
17F X       
18C X X X X 
19A X     X 
19F X X X X 
20 X       
22F X       
23F X X X X 
33F X       
Vaccine   Protective Efficacy*  
Worldwide       China 
Prevnar 7® ~65%         ~64% 
Synflorix® ~80%         ~65% 
Prevnar 13® >85%         >80% 
Pneumococcal Vaccines 
*predictive value 
•24-valent Pneumococcal vaccine 
>95% predicted protection against all 
pneumococcal serotypes worldwide! 
 
•An enabling technology, such as PCMV, 
possesses the capacity to formulate and 
commercialize such vaccines  
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• Preclinical: Pneumococcal PCMV 
 
 
• Clinical:  Vi-CRM197 Typhoid Fever PCMV 
PCMV Proof-of-Principle Strategy 
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Monovalent and Multivalent 
Pneumococcal PCMV 
9 
 Size-Fractionated PPS14-DNI PCMV induced antibody response  
Day 39 anti-PPS14 IgG titers showing mean and standard error of the mean from mice 
immunized with 0.5 µg DNI + PPS14 (left panel). Day 39 anti-PPS14 GMT calculated from 
individual serum titers for mice immunized with 0.5 µg DNI + PPS14 (right panel) 
PCMV induces comparable antibody 
 response to Prevnar at ~15% the dose 
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Passive transfer of anti-PPS14 PCMV sera to mice protects 
against lethal IN pneumococcal challenge  
-mice injected IP with 100 µl of naïve sera or pooled anti-14 
sera (immunized 3x with DNI-PPS14 PCMV; ELISA titer 
1:6900); Virulent S. pneumoniae serotype 14 (1.5 x 108 CFU; 
LD50) was administered intranasally (n= 8 mice/group) 
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• Memory, anamnestic, response demonstrated 
 
• In opsonophagocytic assay (OPA), mouse sera elicited by 
PCMV had a comparable titer to sera induced by Prevnar7®  
 
• Passive transfer of anti-PPS14 sera elicited by PCMV to 
mice confers 100% protection against intranasal challenge 
with serotype14 S. pneumoniae strain 
Monovalent PPS PCMV Immunogenicity 
12 
   
• Matrivax proprietary invention; extends PCMV 
patent life through May 2032 
 
• Facilitates PCMV formation 
 
• Increased efficiency of polysaccharide (PS) 
entrapment into PCMV 
 




Pneumococcal PS-CRM197-MRD517 PCMV Murine Immunogenicity Data  
Trivalent PCMV (PPS 4, 18C, 23F) administered IP induced IgG Antibody Titers 
Results:  PCMV superior to Prevnar 13® at eliciting IgG 




Anti-PPS4  Anti-PPS18C Anti-PPS23F 
Batched Trivalent PCMV* (2 µg each PPS) 
  885,124 76,392 260 
Pneumovax® (2 µg each PPS) 
(23 polysaccharide vaccine)  15 25 19 
Prevnar 13®  (2.2 µg each PPS**) 80,305 3,448 1,194 
Naïve  15 10 13 
* – PPS-CRM197-MRD517 PCMV with alum 
** - 4.4 µg of PPS 6B 
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  Pneumococcal PCMV Current/Next Steps 
•Determine S. pneumoniae PPS bundle compatibility 
 
 
•Introduce S. pneumoniae protective homologous 
 matrix proteins 
 




•Evaluate PPS + protein antigen immunogenicity in mice and 






Vi-CRM197 Typhoid Fever 
PCMV 
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Vi polysaccharide vaccines 
• Generated by fermentation of S. Typhi 
 -Typhim Vi® (sanofi) and Typherix® (GSK) 
• Single (25 µg) dose by injection 
• Licensed for >2 year-olds 
• Protective Efficacy ~70%  
• No memory  
Live attenuated vaccine 
•Live, attenuated S. Typhi Ty2 
 -Vivotif® (Crucell now PaxVax) 
•4 dose enteric coated capsules  
•Protective Efficacy 53-78% 
 
Typhoid fever vaccines  
17 
                     Typhax Immunogenicity in Mice 
Groups Dose (µg) Adjuvant Route of Imm. 
Day 42 
Anti-Vi IgG GMT 
Typhax 0.05 Al-PO4 IM 20,646 
Typhim Vi® 0.05 NONE IM 239 
Naïve -- NONE IM 25 
 Results: 
•Typhax elicits ~86-fold increase in anti-Vi antibody 
compared to Typhim Vi® 
Typhax Preclinical Immunogenicity Summary  
Animal Model Typhax Dose Level 




Mouse 0.05 µg 64 
Rabbit 
0.1 µg 2.4 
2.5 µg 28 
10 µg 34 
NHP 
2.5 µg ~20 
10 µg ~50 
CONFIDENTIAL 18 
• Typhax was formulated at the indicated 
dose levels adjuvanted with 1 mg/mL of 
aluminum phosphate.  
• Mice and rabbits were immunized 
intramuscularly (IM) three times at a 
biweekly interval.  
• Non-human primates (NHP) were 
immunized IM twice at a four week 
interval.  
• Blood was collected two weeks following 
last immunization and the anti-Vi IgG 
antibody titer in the sera was determined 
by ELISA.  
• For mice and rabbits, the fold increase in 
anti-Vi antibody titer over Vi alone is 
reported. For NHP, the fold increase in 
titer relative to pre-immune sera is 
reported.  
CONFIDENTIAL 19 










G1 Typhax 0.2 50 ug Al-PO4 25 13,454 21.8 16,000 15.4 
G2 Typhax 0.05 50 ug Al-PO4 25 32,000 87.2 53,817 61.7 
G3 Typhax 0.01 50 ug Al-PO4 25 13,454 420 32,905 658 
G4 Typhax 0.2 1 mg Adj-1 25 14,672 23.8 45,255 43.6 
G5 Typhax 0.05 1 mg Adj-1 25 7,780 21.2 69,792 80 
G6 Typhax 0.01 1 mg Adj-1 25 2,460 76.9 15,560 311 
G7 Typhax 0.2 1 mg Adj-2 25 53,817 87.2 370,078 357 
G8 Typhax 0.05 1 mg Adj-2 25 41,499 113 180,483 207 
G9 Typhax 0.01 1 mg Adj-2 25 6,747 211 24,675 494 
G10 Typhim Vi  0.2 -- 27 617 -- 1,037 -- 
G11 Typhim Vi  0.05 -- 25 367 -- 872 -- 
G12 Typhim Vi  0.01 -- 25 32 -- 50 -- 
G13 Naïve -- -- 25 25 -- 30 -- 
CONCLUSIONS:  Adjuvanting Typhax with 
Adj-2 results in more robust immune 
response and superior boosting capacity 
compared to adjuvanting with Adj-1 or 
Adju-Phos by day 42 
Murine Immunogenicity Study of  Typhax adjuvanted with Adju-Phos®,  
Adj-1 or -2 compared to Typhim Vi®  
• Balb/C mice immunized IM on day 0, 14, and 28 
• Blood collection on Days -1 (pre-immune), 21, and 
42 
• 8 mice per group  
CONFIDENTIAL 20 
Vi PCMV Adj-2 Rabbit Immunogenicity Study 
• Rabbit study initiated to test immunogenicity of Vi PCMV adjuvanted with Al-
PO4, Adj-1 and Adj-2 
-Vi PCMV 261 synthesized at Matrivax using same Vi polysaccharide used in synthesis of Typhax 
-3 biweekly immunizations 
-Anti-Vi antibody titers determined in sera from blood collected on Day 7, 21 and Day 42 (SAC) 
-Body temp, body weight and injection site monitored during study 
• No significant increase in body temp 3 or 24 hours post immunization 
• No change in body weight 
• No injection site reactivity observed 
Group Dose (µg) 
Route 
of Imm. Description Adjuvant 
No. of 
rabbits Day 0 Day 21 Day 42 
G6 5 IM Vi PCMV 261 500 µg Al-PO4 5 106 80 160 
G7 5 IM Vi PCMV 261 20 mg Adj-1 5 190 190 226 
G8 5 IM Vi PCMV 261 20 mg Adj-2 5 265 5072 3676 
G9 25 IM Typhim Vi NONE 5 121 53 17 
21 
















GMP Vi PCMV Release Status 
• GMP Vi PCMV Fully 
Released: 
-Passed Sterility assay 
-Passed Endotoxin content 
-Passed General Safety Test 
-Met Specifications for: 
• pH 
• Vi content 
• CRM197 content 
 









• GMP Vi PCMV synthesized  March 2014 
• Drug Product Vialed    April 2014 
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• Typhax significantly more immunogenic than Typhim 
Vi® in murine, rabbit, and non-human primates studies 
 
• Toxicology study  
 -No adverse findings 
 -Final report completed 
 
• IND application submission 4Q2015 
 
• Phase 1 safety and immunogenicity study in progress, 
initiated 1Q16 
Vi PCMV (Typhax) Status/Pathway to 
 Phase 1 Clinical Trial 
CONFIDENTIAL 
CONFIDENTIAL 24 
Vi PCMV Phase 1 Clinical Protocol Synopsis 
• Outpatient, dose-escalation clinical trial 
• Inclusion – 18-55 year old healthy volunteers 
• Exclusion – elevated anti-Vi antibody titers  
• One site; n = 45 persons 
• Cohort size: n= 15/dose (3:1:1-Vi PCMV:Typhim Vi®:Placebo) 
• Prime-boost at day 0 and 28, IM, with 6 month follow up 
 
• Dosing - 0.5, 2.5, and 10 µg Vi PCMV  
 
• Key Endpoints  
• Safety (site of injection reactogenicity, etc) 
• Seroconversion (sera collected at day 0, 14, 28, 42, 180) 
• Vi-specific ELISPOT  
• Anti-Vi IgG antibody titers/comparison of Vi PCMV with 
Typhim Vi® 














anti-Vi antibody ELISA 





anti-Vi antibody ELISA 
and PBMC ELISPOT 
Schedule of Typhax Vaccination and Assessments 





•Utilize Vi PCMV as cornerstone 
 -integrate S. paratyphi O-antigen 
 -integrate S. enteriditis O-antigen 
 -integrate S. typhimurium O-antigen 
 
•Create broad based Salmonella vaccine that 
protects against typhoid and paratyphoid fever 







Vi PCMV (Typhax) Project 
• Vi and CRM197 expression and purification know-how technology developed at Matrivax 
• GMP manufacture and release of Vi, CRM197, and MRD517 completed in 2014 
• IND application submitted December 2015 
• Phase 1 clinical trial started 1Q16; adjuvanted study scheduled August 2016  
 
Pneumococcal PCMV Project 
• 3-, 4-, 13-, and 23-valent PPS PCMV elicits dramatic increase in anti-PPS antibody titers 
compared to PPS alone; 6 of 10 PPS PCMV were immunogenically superior to Prevnar13® 
• Simplified PCMV manufacturing process will enable lower COGs and inclusion of 
additional serotypes; project funded by BMGF 
• Proprietary protein antigen evaluation underway; supplement to PS PCMV  
 
C. difficile PCMV Project 
• Proprietary antigen evaluation underway 
• Key immunogenicity and protection data anticipated in 2016 
 
Summary 
CONFIDENTIAL 
